Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
Objective To compare the risk of cardiovascular events between sodium glucose
cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors among …
cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors among …
Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study
B Pasternak, P Ueda, B Eliasson, AM Svensson… - bmj, 2019 - bmj.com
Objective To investigate the cardiovascular effectiveness of sodium glucose cotransporter 2
(SGLT2) inhibitors in routine clinical practice. Design Cohort study using data from …
(SGLT2) inhibitors in routine clinical practice. Design Cohort study using data from …
Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis
Background The risks and benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors on
cardiovascular outcomes have not been well established. We pooled evidence from all …
cardiovascular outcomes have not been well established. We pooled evidence from all …
Cardiovascular outcomes of sodium glucose cotransporter‐2 inhibitors in patients with type 2 diabetes
Aims To determine the association between cardiovascular diseases (CVD) and SGLT2
inhibitors compared to sulfonylureas and dipeptidyl peptidase‐4 (DPP4) inhibitors and to …
inhibitors compared to sulfonylureas and dipeptidyl peptidase‐4 (DPP4) inhibitors and to …
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational …
Background Cardiovascular outcome trials have shown cardiovascular benefit with sodium-
glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes, whereas …
glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes, whereas …
Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus
The benefit or risk of sodium glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular
(CV) outcomes in patients with type 2 diabetes mellitus has not been established. We aimed …
(CV) outcomes in patients with type 2 diabetes mellitus has not been established. We aimed …
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
Y Suzuki, H Kaneko, A Okada, H Itoh… - Cardiovascular …, 2022 - Springer
Background There have been scarce data comparing cardiovascular outcomes between
individual sodium-glucose cotransporter-2 (SGLT2) inhibitors. We aimed to compare the …
individual sodium-glucose cotransporter-2 (SGLT2) inhibitors. We aimed to compare the …
Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized …
Background The impact of sodium–glucose cotransporter-2 (SGLT-2) inhibitors on
cardiovascular outcomes in patients with type II diabetes mellitus (DM) is not well …
cardiovascular outcomes in patients with type II diabetes mellitus (DM) is not well …
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
Objective To assess the association between the use of sodium glucose cotransporter 2
(SGLT2) inhibitors and seven serious adverse events of current concern. Design Register …
(SGLT2) inhibitors and seven serious adverse events of current concern. Design Register …
Effects of sodium‐glucose cotransporter‐2 inhibitors on the cardiovascular and renal complications of type 2 diabetes
RJ Chilton - Diabetes, Obesity and Metabolism, 2020 - Wiley Online Library
Abstract Sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) have been shown to
mitigate the risks of cardiovascular (CV) and renal complications in patients with type 2 …
mitigate the risks of cardiovascular (CV) and renal complications in patients with type 2 …
相关搜索
- cardiovascular outcomes sodium glucose
- meta analysis sodium glucose
- sglt2 inhibitors cardiovascular events
- cause mortality sodium glucose
- cardiovascular outcomes inhibitors in patients
- cvd real cardiovascular events
- diabetes mellitus sodium glucose
- renal complications sodium glucose
- sglt2 inhibitors cardiovascular outcomes